Skip to content
Loading…
AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.